pharma · Duchenne Muscular Dystrophy · Muscular Dystrophy, Duchenne · SRPT
Sarepta Therapeutics
Sarepta Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker SRPT. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Muscular Dystrophy, Duchenne, Duche
215 First Street, Cambridge, MA 02142, US HQ
1,150 Employees
Public company Type
SRPT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 215 First Street, Cambridge, MA 02142, US
- Employees
- 1,150
- Programs
- 46
- Drugs
- 23
- Patents
- 102
SRP-9003-301
Phase 3 · small molecule · Limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4) or β-sarcoglycanopathy
SRP-9003-301 for Limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4) or β-sarcoglycanopathy is a Phase 3 program (small_molecule) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code SRP-9003-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sarepta Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4) or β-sarcoglycanopathy
- Status
- active
- Trials
- 1